Novartis reports Phase III data showing omalizumab improved itch in patients with a chronic form of hives who failed standard therapy[1]
24 February 2013 | By Novartis
Late-breaking results from ASTERIA II...
List view / Grid view
24 February 2013 | By Novartis
Late-breaking results from ASTERIA II...
15 February 2013 | By Novartis
The FDA has approved Zortress®...
23 January 2013 | By Novartis
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia...
22 January 2013 | By Novartis
Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe...
18 January 2013 | By Novartis
"Novartis welcomes the decision by the CHMP in support of the approval of Ilaris in the EU"
18 January 2013 | By Novartis
Jetrea(TM) would become the first drug to treat sight-threatening vitreomacular traction and macular hole...
17 January 2013 | By Novartis
"The challenges in delivering healthcare in developing countries are considerable..."
14 January 2013 | By Novartis
Findings from a pivotal Phase III clinical trial...
11 January 2013 | By Novartis
Data published today...
21 December 2012 | By Novartis
The EC has approved Exjade®...
15 December 2012 | By Novartis
The US FDA has approved Signifor®...
11 December 2012 | By Novartis
Novartis announced long-term follow-up data...
10 December 2012 | By Novartis
Latest results from two Phase III clinical trials...
4 December 2012 | By Novartis
Healthcare experts assess psychosocial approaches and interventions...
28 November 2012 | By Novartis
More than 140 presentations on key data...